Drug Trial Radar · NCT07049107
Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Jun 23, 2025
Primary completion
Jul 21, 2025
Study completion Jul 21, 2025
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, open-label, sequential drug interaction study The primary objectives are: To evaluate the pharmacokinetic effects of HRS-8427 injection on the liver drug enzymes CYP2B6 substrate bupropion and CYP3A4 substrate midazolam in healthy subjects.
Conditions
- Health Volunteer
Interventions
HRS-8427Drug
HRS-8427
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: 15 Days
- AUC0-tTime frame: 15 Days
- AUC0-∞Time frame: 15 Days
- TmaxTime frame: 15 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xiangya Hospital Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.